EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieVergleichsstudie

Bioequivalence Study of 2 Formulations of Fluticasone Nasal Spray in Healthy Chinese Volunteers

Gang Chen, Zejuan Wang, Xiaona Liu, Aihua Du, Min Li, Yanan Zhang, Dan Zhang, Xiaolin Wang, Xueyan Li, Wei Cong, Jin Wang

Clinical Pharmacology in Drug Development · 2025

DOI: 10.1002/cpdd.1505 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical Pharmacology in Drug Development, 2025. Verfasst von Gang Chen und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacology, Aerospace Center Hospital, Beijing, China. Hauptthemen laut MEDLINE: Fluticasone. Die Arbeit nennt 17 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study aimed to evaluate the pharmacokinetic characteristics, safety, and bioequivalence of 2 formulations of fluticasone nasal spray in healthy Chinese subjects. A single‐center, randomized, open‐label, single‐dose, 2‐formulation, 2‐sequence, 2‐period crossover bioequivalence study was conducted under fasting conditions. A total of 120 healthy male and female subjects were enrolled, of which 119 subjects completed the entire study. The main pharmacokinetic parameters of the parent drug, fluticasone propionate (FP), in plasma were as follows: For the test formulation, maximum plasma concentration (C max ) was 10.3 pg/mL, area under the plasma concentration–time curve from time zero to the last quantifiable concentration (AUC 0‐t ) was 65.6 pg•h/mL, and area under the plasma concentration–time curve from time zero to infinity (AUC 0‐∞ ) was 86.4 pg•h/mL. For the reference formulation: C max was 8.80 pg/mL, AUC 0‐t was 58.2 pg•h/mL, and AUC 0‐∞ was 75.2 pg•h/mL. The 90% confidence intervals of the geometric means for AUC 0‐t , AUC 0‐∞ , and C max between the 2 formulations were 105%‐120%, 103%‐120%, and 112%‐124%, respectively. The results show that the test and reference formulations were well tolerated, with no serious adverse events reported. According to the criteria for bioequivalence, the FP nasal spray (test formulation) is bioequivalent to the reference formulation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FluticasoneAdolescentAdultFemaleHumansMaleMiddle AgedYoung AdultAdministration, IntranasalArea Under CurveChinaCross-Over StudiesHealthy VolunteersNasal SpraysTherapeutic EquivalencyEast Asian People

Stichwörter der Autor:innen

bioequivalencefluticasone propionatenasal spray

Substanzen

FluticasoneNasal Sprays

Autor:innen und Institutionen

  • Department of Clinical Pharmacology, Aerospace Center Hospital, Beijing, China.

Zitieren

APA

Chen, G., Wang, Z., Liu, X., Du, A., Li, M., Zhang, Y., Zhang, D., Wang, X., Li, X., Cong, W., & Wang, J. (2025). Bioequivalence Study of 2 Formulations of Fluticasone Nasal Spray in Healthy Chinese Volunteers. Clinical Pharmacology in Drug Development. https://doi.org/10.1002/cpdd.1505

Vancouver

Chen G, Wang Z, Liu X, Du A, Li M, Zhang Y, et al. Bioequivalence Study of 2 Formulations of Fluticasone Nasal Spray in Healthy Chinese Volunteers. Clinical Pharmacology in Drug Development. 2025. doi:10.1002/cpdd.1505

BibTeX
@article{Chen2025,
  author = {Chen, Gang and Wang, Zejuan and Liu, Xiaona and Du, Aihua and Li, Min and Zhang, Yanan and Zhang, Dan and Wang, Xiaolin and Li, Xueyan and Cong, Wei and Wang, Jin},
  title = {Bioequivalence Study of 2 Formulations of Fluticasone Nasal Spray in Healthy Chinese Volunteers},
  journal = {Clinical Pharmacology in Drug Development},
  year = {2025},
  doi = {10.1002/cpdd.1505}
}
Kostenlos starten →